Compare Aurora Cannabis Inc (ACB) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aurora Cannabis Inc vs Carlyle Group Inc — how do they compare? Aurora Cannabis Inc trades at $3.45 (market cap $178.92M), while Carlyle Group Inc trades at $48.27 (market cap $17.20B). The key difference: Carlyle Group Inc is far larger — about 96.1× Aurora Cannabis Inc's market cap, and Carlyle Group Inc pays a 2.93% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | CG | |
|---|---|---|
Market Cap | $178.92M | $17.20B |
Sector | Health | Financials |
52-Week High | $6.23 | $69.35 |
52-Week Low | $2.58 | $40.52 |
Enterprise Value | $123.48M | — |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.
ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.
CG trades at $47.79, down 2.23% today, with a bullish technical signal from moving averages and support at $47. Recent Q2 2026 earnings beat expectations (EPS $1.07 vs. $0.911), though revenue declined to $2.9B in 2026. The company maintains a strong net income margin of 18.85% and announced strategic partnerships, including a $600M deal with Prime Capital Financial (Business Wire, 2026-08-06).
Outlook is mixed: analyst consensus is bullish with a $59.14 price target (53.84% buy ratings), but risks include volatile cash flow from operations (-$4.2B in 2026) and high P/E of 49.78. Investors may see upside from fundraising strength, though margin compression and macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
